Bronchogen (AEDL) is a synthetic tetrapeptide bioregulator consisting of the amino acid sequence Alanine-Glutamic acid-Aspartic acid-Leucine. Developed as part of Vladimir Khavinson’s bioregulator peptide research programme at the St. Petersburg Institute of Bioregulation and Gerontology, it belongs to a class of short peptides capable of penetrating cellular and nuclear membranes to interact directly with DNA.
Bronchogen preferentially binds to CNG sequences (targets for cytosine methylation) and the guanine N7 site, stabilising DNA structure and modulating chromatin via histone interactions. It regulates lung specific genes including NKX2-1, SCGB1A1, and FOXA1/2, promoting bronchial epithelial differentiation and influencing inflammatory signalling in respiratory tissue models.
